Item 1. FINANCIAL STATEMENTS

155K characters. Original on sec.gov · Markdown

Item 1. FINANCIAL STATEMENTS


Condensed Consolidated Statements of Income (Unaudited)
	For the three months ended June 30				For the six months ended June 30
(In millions, except per share amounts)	2026		2025		2026		2025
Sales of products	$	3,416	$	3,263	$	6,762	$	6,380
Sales of services	1,878		1,743		3,664		3,404
Total revenues	5,295		5,007		10,425		9,784
Cost of products	2,217		2,160		4,500		4,122
Cost of services	898		863		1,769		1,665
Gross profit	2,180		1,985		4,157		3,997
Selling, general, and administrative	1,118		1,029		2,235		2,069
Research and development	323		302		668		646
Total operating expenses	1,441		1,331		2,903		2,714
Operating income	739		654		1,254		1,283
Interest and other financial charges – net	114		113		210		224
Non-operating benefit (income) costs	(45)		(73)		(96)		(148)
Other (income) expense – net	(22)		1		(58)		(98)
Income before income taxes	693		613		1,198		1,304
Benefit (provision) for income taxes	(119)		(113)		(213)		(216)


Net income	573		500		985		1,088
Net (income) loss attributable to noncontrolling interests	(13)		(14)		(35)		(39)
Net income attributable to GE HealthCare	$	561	$	486	$	950	$	1,049






Earnings per share attributable to GE HealthCare:
Basic	$	1.24	$	1.06	$	2.09	$	2.30
Diluted	1.24		1.06		2.08		2.29
Weighted-average number of shares outstanding:
Basic	453		457		454		457
Diluted	454		458		456		459

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents


Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited)

	For the three months ended June 30				For the six months ended June 30
(In millions)	2026		2025		2026		2025
Net income attributable to GE HealthCare	$	561	$	486	$	950	$	1,049
Net income (loss) attributable to noncontrolling interests	13		14		35		39
Net income	573		500		985		1,088
Other comprehensive income (loss):

Currency translation adjustments – net of taxes	(71)		221		(97)		478
Pension and Other Postretirement Plans – net of taxes	(18)		(79)		(28)		(148)
Cash flow hedges – net of taxes	8		(33)		25		(41)
Other comprehensive income (loss)	(80)		108		(100)		288
Comprehensive income (loss)	493		608		885		1,376
Less: Comprehensive income (loss) attributable to noncontrolling interests	14		14		27		39
Comprehensive income attributable to GE HealthCare	$	479	$	594	$	858	$	1,338

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents


Condensed Consolidated Statements of Financial Position (Unaudited)
	As of
(In millions, except share and per share amounts)	June 30, 2026		December 31, 2025
Cash, cash equivalents, and restricted cash	$	2,105	$	4,512
Receivables – net of allowances of $102 and $103	3,881		3,955

Inventories	2,483		2,234
Contract and other deferred assets	1,235		1,073
All other current assets	793		726
Current assets	10,497		12,501
Property, plant, and equipment – net	3,146		3,092
Goodwill	15,095		13,489
Other intangible assets – net	1,894		1,130
Deferred income taxes	4,359		4,491
All other non-current assets	2,254		2,205
Total assets	$	37,246	$	36,906
Short-term borrowings	$	2	$	508
Accounts payable	3,231		3,250

Contract liabilities	2,200		2,095
Current compensation and benefits	1,439		1,666
All other current liabilities	1,429		1,587
Current liabilities	8,302		9,105
Long-term borrowings	10,091		9,495
Non-current compensation and benefits	5,186		5,453
Deferred income taxes	315		193
All other non-current liabilities	2,133		2,061
Total liabilities	26,027		26,307
Commitments and contingencies
Redeemable noncontrolling interests	229		209
Common stock, par value $0.01 per share, 1,000,000,000 shares authorized, 459,470,464 shares issued as of June 30, 2026; 458,844,209 shares issued as of December 31, 2025	5		5
Treasury stock, at cost, 7,785,199 shares as of June 30, 2026 and 3,107,626 shares as of December 31, 2025	(525)		(225)
Additional paid-in capital	6,776		6,707
Retained earnings	6,199		5,281

Accumulated other comprehensive income (loss) – net	(1,480)		(1,388)
Total equity attributable to GE HealthCare	10,975		10,379
Noncontrolling interests	14		11
Total equity	10,989		10,390
Total liabilities, redeemable noncontrolling interests, and equity	$	37,246	$	36,906

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents


Condensed Consolidated Statements of Changes in Equity (Unaudited)
	Common stock			Treasury stock
(In millions, except per share amounts)	Shares	Amount		Shares	Amount		Additional paid-in capital		Retained earnings		Accumulated other comprehensive income (loss) – net		Equity attributable to noncontrolling interests		Total equity
Balances as of March 31, 2026	459	$	5	5	$	(325)	$	6,733	$	5,654	$	(1,398)	$	12	$	10,680
Issuance of shares under equity awards, net of shares withheld for taxes and other	—	—		—	—		(1)		—		—		—		(1)
Repurchase of common stock	—	—		3	(200)		—		—		—		—		(200)
Net income attributable to GE HealthCare	—	—		—	—		—		561		—		—		561
Dividends declared ($0.035 per common share)	—	—		—	—		—		(16)		—		—		(16)
Other comprehensive income (loss) attributable to GE HealthCare	—	—		—	—		—		—		(81)		—		(81)
Changes in equity attributable to noncontrolling interests	—	—		—	—		—		—		—		2		2
Share-based compensation	—	—		—	—		45		—		—		—		45
Balances as of June 30, 2026	459	$	5	8	$	(525)	$	6,776	$	6,199	$	(1,480)	$	14	$	10,989



	Common stock			Treasury stock
(In millions, except per share amounts)	Shares	Amount		Shares	Amount		Additional paid-in capital		Retained earnings		Accumulated other comprehensive income (loss) – net		Equity attributable to noncontrolling interests		Total equity
Balances as of March 31, 2025	458	$	5	—	$	(25)	$	6,597	$	3,810	$	(1,199)	$	20	$	9,207
Issuance of shares under equity awards, net of shares withheld for taxes and other	—	—		—	—		(3)		—		—		—		(3)
Repurchase of common stock	—	—		1	(100)		—		—		—		—		(100)
Net income attributable to GE HealthCare	—	—		—	—		—		486		—		—		486

Other comprehensive income (loss) attributable to GE HealthCare	—	—		—	—		—		—		109		—		109
Changes in equity attributable to noncontrolling interests	—	—		—	—		—		—		—		1		1
Share-based compensation	—	—		—	—		34		—		—		—		34
Balances as of June 30, 2025	458	$	5	2	$	(125)	$	6,628	$	4,295	$	(1,090)	$	21	$	9,733

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents


Condensed Consolidated Statements of Changes in Equity (Unaudited)
	Common stock			Treasury stock
(In millions, except per share amounts)	Shares	Amount		Shares	Amount		Additional paid-in capital		Retained earnings		Accumulated other comprehensive income (loss) – net		Equity attributable to noncontrolling interests		Total equity
Balances as of December 31, 2025	459	$	5	3	$	(225)	$	6,707	$	5,281	$	(1,388)	$	11	$	10,390
















Issuance of shares under equity awards, net of shares withheld for taxes and other	1	—		—	—		(10)		—		—		—		(10)
Repurchase of common stock	—	—		5	(300)		—		—		—		—		(300)
Net income attributable to GE HealthCare	—	—		—	—		—		950		—		—		950
Dividends declared ($0.070 per common share)	—	—		—	—		—		(32)		—		—		(32)
Other comprehensive income (loss) attributable to GE HealthCare	—	—		—	—		—		—		(92)		—		(92)
Changes in equity attributable to noncontrolling interests	—	—		—	—		—		—		—		4		4
Share-based compensation	—	—		—	—		80		—		—		—		80
Balances as of June 30, 2026	459	$	5	8	$	(525)	$	6,776	$	6,199	$	(1,480)	$	14	$	10,989



	Common stock			Treasury stock
(In millions, except per share amounts)	Shares	Amount		Shares	Amount		Additional paid-in capital		Retained earnings		Accumulated other comprehensive income (loss) – net		Equity attributable to noncontrolling interests		Total equity
Balances as of December 31, 2024	457	$	5	—	$	(25)	$	6,583	$	3,262	$	(1,379)	$	18	$	8,464
Issuance of shares under equity awards, net of shares withheld for taxes and other	1	—		—	—		(11)		—		—		—		(11)
Repurchase of common stock	—	—		1	(100)		—		—		—		—		(100)
Net income attributable to GE HealthCare	—	—		—	—		—		1,049		—		—		1,049
Dividends declared ($0.035 per common share)	—	—		—	—		—		(16)		—		—		(16)
Other comprehensive income (loss) attributable to GE HealthCare	—	—		—	—		—		—		288		—		288
Changes in equity attributable to noncontrolling interests	—	—		—	—		—		—		—		2		2
Share-based compensation	—	—		—	—		56		—		—		—		56
Balances as of June 30, 2025	458	$	5	2	$	(125)	$	6,628	$	4,295	$	(1,090)	$	21	$	9,733

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents


Condensed Consolidated Statements of Cash Flows (Unaudited)
	For the six months ended June 30
(In millions)	2026		2025
Net income	$	985	$	1,088


Adjustments to reconcile Net income to Cash from (used for) operating activities:
Depreciation of property, plant, and equipment	154		138
Amortization of intangible assets	159		146
Gain on remeasurement of Nihon Medi-Physics equity method investment	—		(97)
Net periodic postretirement benefit plan (income) expense	(93)		(138)
Postretirement plan contributions	(171)		(182)
Share-based compensation	80		56
Provision for income taxes	213		216
Cash paid during the year for income taxes	(231)		(270)
Changes in operating assets and liabilities, excluding the effects of acquisitions:
Receivables	62		185
Inventories	(310)		(188)
Contract and other deferred assets	(132)		(48)
Accounts payable	21		(113)
Contract liabilities	83		(23)
Current compensation and benefits	(231)		(207)
All other operating activities – net	(130)		(218)
Cash from (used for) operating activities	458		344
Cash flows – investing activities
Additions to property, plant and equipment and internal-use software	(278)		(238)

Purchases of businesses, net of cash acquired	(2,293)		(279)
Purchases of investments	(19)		(28)
All other investing activities – net	(24)		(84)
Cash from (used for) investing activities	(2,615)		(630)
Cash flows – financing activities
Net increase (decrease) in borrowings (maturities of 90 days or less)	(1)		1
Newly issued debt, net of debt issuance costs (maturities longer than 90 days)	1,152		1,493
Repayments and other reductions (maturities longer than 90 days)	(1,012)		(261)
Dividends paid to stockholders	(32)		(32)
Repurchase of common stock	(300)		(100)


Proceeds from stock issued under employee benefit plans	10		21
Taxes paid related to net share settlement of equity awards	(21)		(33)
All other financing activities – net	(12)		(15)
Cash from (used for) financing activities	(215)		1,075



Effect of foreign currency rate changes on cash, cash equivalents, and restricted cash	(35)		84
Increase (decrease) in cash, cash equivalents, and restricted cash	(2,407)		873
Cash, cash equivalents, and restricted cash at beginning of year	4,515		2,893

Cash, cash equivalents, and restricted cash at end of period	$	2,108	$	3,766

Supplemental disclosure of cash flows information
Cash paid during the year for interest	$	(280)	$	(260)
Non-cash investing activities
Acquired but unpaid property, plant, and equipment	$	102	$	90

The accompanying notes are an integral part of these condensed consolidated financial statements.

Table of Contents

NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1. ORGANIZATION AND BASIS OF PRESENTATION

GE HealthCare Technologies Inc. is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions.

The condensed consolidated financial statements (the “financial statements”) of GE HealthCare Technologies Inc. and its subsidiaries (“GE HealthCare,” the “Company,” “our,” “us,” or “we”) have been prepared in accordance with United States (“U.S.”) generally accepted accounting principles (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, the financial statements do not include all of the information and notes required by U.S. GAAP for complete financial statements. In the opinion of management, all adjustments, including normal recurring adjustments, considered necessary for a fair presentation of the Company’s financial position and operating results have been included. All intercompany balances and transactions within the Company have been eliminated in the financial statements. Operating results for the three and six months ended June 30, 2026 and 2025 are not necessarily indicative of the results that may be expected for the fiscal year as a whole. The December 31, 2025 period presented on the Condensed Consolidated Statement of Financial Position was derived from audited financial statements but does not include all disclosures required by U.S. GAAP.

The financial statements and notes should be read in conjunction with the Company’s audited consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025. Tables throughout this document are presented in millions of U.S. dollars unless otherwise stated and certain columns and rows may not sum due to the use of rounded numbers. Percentages presented are calculated from the underlying whole-dollar amounts. References to the “Spin-Off” are related to the spin-off of GE HealthCare Technologies Inc. from General Electric Company, which now operates as GE Aerospace (“GE”).

In the second quarter of 2026, we made a strategic change to our executive leadership and to our segments, combining our Imaging and Advanced Visualization Solutions (“AVS”) businesses into a new operating and reportable segment, Advanced Imaging Solutions (“AIS”). Following this organizational change, the Company has three reportable segments: AIS, Pharmaceutical Diagnostics (“PDx”), and Patient Care Solutions (“PCS”), which is aligned with how the Company’s Chief Operating Decision Maker (“CODM”) reviews the business for the purpose of assessing performance and allocating resources. Historical segment financial information presented within this report has been recast to conform to the new reportable segment structure. See Note 3, “Segment Information” for more information.

ESTIMATES AND ASSUMPTIONS.

The preparation of the financial statements in conformity with U.S. GAAP requires management to make estimates based on assumptions about current, and for some estimates, future, economic and market conditions, which affect the reported amounts and related disclosures in the financial statements. We base our estimates and judgments on historical experience and on various other assumptions and information that we believe to be reasonable under the circumstances. Although our estimates contemplate current and expected future conditions, as applicable, it is reasonably possible that actual conditions could differ from our expectations, which could materially affect our results of operations, financial position, and cash flows.

RECENT ACCOUNTING PRONOUNCEMENTS.

We evaluate Accounting Standards Updates (“ASUs”) issued by the Financial Accounting Standards Board (“FASB”). ASUs not included in our disclosures were assessed and determined to either be not applicable or are not expected to have a significant impact on our financial statements or disclosures.

In November 2024, the FASB issued ASU No. 2024-03 (“ASU 2024-03”), Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses. ASU 2024-03 addresses investor requests for more transparency about expense information through the disaggregation of relevant expense captions in the notes to the financial statements. The provisions of ASU 2024-03 are effective for fiscal years beginning after December 15, 2026 and interim periods within fiscal years beginning after December 15, 2027. We expect the adoption to increase disclosures in our notes to the financial statements.

In September 2025, the FASB issued ASU No. 2025-06 (“ASU 2025-06”), Intangibles - Goodwill and Other - Internal-Use Software (subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software. ASU 2025-06 updates the accounting for internal-use software by eliminating the concept of development stages. Under the updated guidance, software costs are capitalized once management has authorized and committed to funding the project, and it is probable the project will be completed and the software will be used to perform the function intended. The provisions of ASU 2025-06 are effective for annual reporting periods beginning after December 15, 2027, and interim periods within those annual periods. We are currently evaluating the effect that ASU 2025-06 will have on our financial statements.

Table of Contents

NOTE 2. REVENUE RECOGNITION

Our revenues primarily consist of sales of products and services to customers. Products include equipment, imaging agents, software-related offerings, and upgrades. Services include contractual and stand-by preventative maintenance and corrective services, as well as related parts and labor, extended warranties, training, and other service-type offerings. The Company recognizes revenue from contracts with customers when the customer obtains control of the underlying products or services.

CONTRACT AND OTHER DEFERRED ASSETS.

Contract assets reflect revenue recognized on contracts with customers in excess of billings based on contractual terms. Contract assets are classified as current or non-current based on the amount of time expected to lapse until the Company’s right to consideration becomes unconditional. Other deferred assets consist of costs to obtain contracts, primarily commissions, other cost deferrals for shipped products, and deferred service, labor, and direct overhead costs.


	As of
	June 30, 2026		December 31, 2025
Contract assets	$	776	$	645
Other deferred assets	459		428
Contract and other deferred assets	1,235		1,073
Non-current contract assets(1)	91		91
Non-current other deferred assets(1)	125		120
Total contract and other deferred assets	$	1,452	$	1,285

(1)Non-current contract and other deferred assets are recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.

CONTRACT LIABILITIES.

Contract liabilities include customer advances and deposits received when orders are placed and billed in advance of completion of performance obligations. Contract liabilities are classified as current or non-current based on the periods over which these remaining performance obligations are expected to be satisfied with our customers.


	As of
	June 30, 2026		December 31, 2025
Contract liabilities	$	2,200	$	2,095
Non-current contract liabilities(1)	857		803
Total contract liabilities	$	3,057	$	2,899

(1)Non-current contract liabilities are recognized within All other non-current liabilities in the Condensed Consolidated Statements of Financial Position.

Revenue recognized related to the contract liabilities balance at the beginning of the year was approximately $1,189 million and $1,134 million for the six months ended June 30, 2026 and 2025, respectively.

REMAINING PERFORMANCE OBLIGATIONS.

Remaining performance obligations (“RPO”) represents the estimated revenue expected from customer contracts that are partially or fully unperformed inclusive of amounts deferred in contract liabilities, excluding contracts, or portions thereof, that provide the customer with the right to cancel or terminate without incurring a substantive penalty. RPO also excludes estimated revenue from arrangements where we lease equipment manufactured by the Company to customers.


	As of
	June 30, 2026		December 31, 2025
Products	$	5,180	$	5,001
Services	10,939		10,728
Total RPO	$	16,118	$	15,729

We expect to recognize substantially all of the revenue for our product-related RPO within two years and services-related RPO within five years.

Table of Contents

NOTE 3. SEGMENT INFORMATION

In the second quarter of 2026, we made a strategic change to our executive leadership and to our segments, combining our Imaging and AVS businesses into a new operating and reportable segment, Advanced Imaging Solutions. The AIS segment has a product portfolio that serves customers across three core areas: Radiology, Specialized Ultrasound, and Procedural Guidance. Radiology was formerly reported as our Imaging business, while Specialized Ultrasound and Procedural Guidance were previously reported in our AVS business. Historical segment financial information presented within this report has been recast to conform to the new reportable segment structure.

Following this organizational change, the Company has three reportable segments: AIS, PDx, and PCS. These segments have been identified based on the nature of the products sold and how the Company manages its operations. We have not aggregated any of our operating segments to form reportable segments.

The Company’s organizational structure is based upon the availability of separate financial information that is evaluated regularly by the Company’s CODM for the purpose of assessing performance and allocating resources. The Company’s CODM is our Chief Executive Officer. The CODM assesses segment performance using Total revenues and an earnings metric defined as “Segment EBIT.” Segment EBIT is calculated as Income before income taxes in our Condensed Consolidated Statements of Income excluding the impact of the following: Interest and other financial charges – net, Non-operating benefit (income) costs, restructuring costs, acquisition and disposition-related benefits (charges), gain (loss) on business and asset dispositions, Spin-Off and separation costs and other adjustments, amortization of acquisition-related intangible assets, investment revaluation gain (loss), and other non-recurring items such as refunds for tariffs incurred in prior years. Segment EBIT is also used in the annual budget and periodic forecasting processes and informs the CODM in decision making regarding the allocation of resources to the segments.


Total Revenues by Segment	For the three months ended June 30				For the six months ended June 30
	2026		2025		2026		2025
AIS:
Radiology	$	2,388	$	2,204	$	4,686	$	4,344
Procedural Guidance	715		660		1,434		1,301
Specialized Ultrasound	668		630		1,290		1,228
Total AIS	3,771		3,493		7,410		6,872
Total PDx	843		729		1,612		1,362
PCS:
Monitoring Solutions	503		578		1,022		1,135
Life Support Solutions	172		200		357		397
Total PCS	675		778		1,379		1,531
Other(1)	6		6		24		19
Total revenues	$	5,295	$	5,007	$	10,425	$	9,784

(1) Financial information not presented within the reportable segments, shown within the Other category, represents HealthCare Financial Services (“HFS”), which does not meet the definition of an operating segment.


Significant Expenses by Segment	For the three months ended June 30				For the six months ended June 30
	2026		2025		2026		2025
AIS:
Cost of sales	$	2,254	$	2,106	$	4,458	$	4,057
Other segment items(1)	992		932		1,948		1,901
Total AIS	$	3,246	$	3,039	$	6,407	$	5,958
PDx:
Cost of sales	$	422	$	371	$	828	$	666
Other segment items(1)	171		144		338		278
Total PDx	$	593	$	516	$	1,166	$	943
PCS:
Cost of sales	$	494	$	507	$	975	$	988
Other segment items(1)	207		212		420		436
Total PCS	$	700	$	719	$	1,395	$	1,423

(1) Other segment items for each segment includes selling, general, administrative, research, and development related expenses, as well as other segment income and expenses.

Table of Contents


Segment EBIT	For the three months ended June 30				For the six months ended June 30
	2026		2025		2026		2025
Segment EBIT
AIS	$	525	$	455	$	1,004	$	914
PDx	250		213		446		418
PCS	(26)		60		(16)		108
Other(1)	1		1		6		3
	750		729		1,440		1,443
Restructuring costs	(27)		(18)		(76)		(40)
Acquisition and disposition-related benefits (charges)	(11)		(7)		(46)		(15)
Gain (loss) on business and asset dispositions	—		(5)		—		5
Spin-Off and separation costs and other adjustments	5		(5)		2		(29)
Amortization of acquisition-related intangible assets	(61)		(40)		(108)		(75)
Investment revaluation gain (loss)	—		(1)		(8)		92
Interest and other financial charges – net	(114)		(113)		(210)		(224)
Non-operating benefit income (costs)	45		73		96		148
Tariff refunds	106		—		106		—
Income before income taxes	$	693	$	613	$	1,198	$	1,304

(1) Financial information not presented within the reportable segments, shown within the Other category, primarily represents HFS, which does not meet the definition of an operating segment.

The following table represents the depreciation and amortization amounts reported within the Segment EBIT metric for our reportable segments. Depreciation and amortization expense related to shared property, plant, and equipment and intangibles, exclusive of acquisition-related intangible assets, has been fully allocated to our segments and those allocations are reflected in the amounts presented in the table below. These amounts are included within Cost of sales and Other segment items disclosed in the Significant Expenses by Segment table above.


Depreciation and Amortization by Segment	For the three months ended June 30				For the six months ended June 30
	2026		2025		2026		2025

AIS	$	67	$	75	$	139	$	151
PDx	19		17		39		29
PCS	13		13		25		27

The Company does not report total assets by segment as the Company’s CODM does not assess performance, make strategic decisions, or allocate resources based on assets.

NOTE 4. RECEIVABLES


Current Receivables	As of
	June 30, 2026		December 31, 2025
Current customer receivables(1)	$	3,535	$	3,719
Non-income based tax receivables	169		159
Other sundry receivables	279		180
Current sundry receivables	448		339
Allowance for credit losses	(102)		(103)
Total current receivables – net	$	3,881	$	3,955

(1) Chargebacks, which are primarily related to our PDx business, are generally settled through issuance of credits, typically within one month of initial recognition, and are recorded as a reduction to Current customer receivables. Balances related to chargebacks were $103 million and $148 million as of June 30, 2026 and December 31, 2025, respectively. The decrease in chargebacks is primarily due to lower wholesaler product levels.

Table of Contents


Long-Term Receivables	As of
	June 30, 2026		December 31, 2025
Long-term customer receivables	$	77	$	73
Non-income based tax receivables	25		24
Other sundry receivables	88		100
Long-term sundry receivables	112		124

Allowance for credit losses	(7)		(7)
Total long-term receivables – net	$	183	$	190

Long-term receivables are recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.

NOTE 5. FINANCING RECEIVABLES

Current financing receivables and non-current financing receivables are recognized within All other current assets and All other non-current assets, respectively, in the Condensed Consolidated Statements of Financial Position.



	As of
	June 30, 2026		December 31, 2025
Loans receivable, at amortized cost	$	21	$	21
Investment in finance leases, net of deferred income	74		76
Allowance for credit losses	(3)		(2)
Current financing receivables – net	$	92	$	95

Loans receivable, at amortized cost	$	45	$	44
Investment in finance leases, net of deferred income	149		149
Allowance for credit losses	(3)		(3)
Non-current financing receivables – net	$	191	$	190

As of June 30, 2026, 2%, 1%, and 2% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral. As of December 31, 2025, 1%, 1%, and 1% of financing receivables were over 30 days past due, over 90 days past due, and on nonaccrual, respectively, with the majority of nonaccrual financing receivables secured by collateral.

NOTE 6. OPERATING LEASES

As a lessee, the Company leases certain logistics, office, and manufacturing facilities, as well as vehicles and other equipment. Certain of the Company’s leases may include options to extend. Our operating lease right-of-use (“ROU”) assets are recognized within Property, plant, and equipment – net and our operating lease liabilities are recognized within All other current liabilities and All other non-current liabilities in the Condensed Consolidated Statements of Financial Position, as detailed below.


Operating Lease Assets and Liabilities	As of
	June 30, 2026		December 31, 2025
Operating lease ROU assets, net of amortization	$	391	$	410
Current operating lease liabilities	131		134
Non-current operating lease liabilities	263		284
Total operating lease liabilities	$	394	$	419

The total lease expense related to our operating lease portfolio was $60 million for both the three months ended June 30, 2026 and 2025, and $123 million and $122 million for the six months ended June 30, 2026 and 2025, respectively.

Table of Contents

NOTE 7. ACQUISITIONS, GOODWILL, AND OTHER INTANGIBLE ASSETS

ACQUISITIONS.

Intelerad

On March 18, 2026, the Company acquired 100% of the stock of Intelerad for approximately $2,293 million in cash, net of cash acquired. The purchase was funded by the proceeds of senior unsecured notes issued in the fourth quarter of 2025, together with new borrowings under a delayed draw term loan facility and cash on hand. See Note 8, “Borrowings” for additional information on the borrowings. Intelerad is included in the Company’s AIS segment.

Intelerad is a leading medical imaging software and digital enterprise workflow solutions company with a significant presence in outpatient ambulatory care settings, which the Company believes complements our strength in hospital-based imaging.

The preliminary fair values of the assets and liabilities assumed in connection with the acquisition of Intelerad are as follows.


	Preliminary allocation
Receivables	$	39
Contract assets	27

Property, plant, and equipment	9
Goodwill	1,629
Other intangible assets	845
All other current and non-current assets	28
Accounts payable	(16)
Contract liabilities	(34)
Other current liabilities	(23)
Deferred income taxes	(123)
All other non-current liabilities(1)	(88)

Total net assets post acquisition	$	2,293

(1) All other non-current liabilities primarily includes tax reserves.

The purchase price allocation required estimates and assumptions, including, but not limited to, estimates of future cash flows, direct costs, and appropriate discount rates. During the three months ended June 30, 2026, the Company reassessed its estimates and inputs as new information about facts and circumstances that existed as of the acquisition date became known. As a result, the Company recorded a net increase of $45 million to goodwill. These adjustments primarily relate to Contract assets, Deferred income taxes, and Other intangible assets. While all amounts remain subject to adjustments, the areas subject to the most significant potential adjustments are Other intangible assets and Deferred income taxes. The Company’s management believes the amounts recognized for the assets acquired and liabilities assumed are based on reasonable estimates and assumptions.

Other intangibles relate to $845 million of definite-lived intangible assets, primarily consisting of developed technology, customer relationships, and trade names. The acquired definite-lived intangibles are being amortized over a weighted-average estimated useful life of approximately 12 years. The estimated fair value of intangibles was determined using the income approach, which is a valuation technique that provides an estimate of the fair value of an asset based on market participant expectations of cash flows an asset would generate over its useful life.

Goodwill recognized in connection with the Intelerad acquisition, recorded within the AIS segment, is not deductible for income tax purposes. The goodwill primarily reflects expected synergies and other strategic benefits associated with the integration of Intelerad’s technology into the Company’s market offerings and imaging technologies.

Deferred income tax liabilities include the expected U.S. federal, state, and foreign tax consequences associated with temporary differences between the preliminary fair values of the assets acquired and liabilities assumed and the respective tax basis.

Our unaudited supplemental pro forma consolidated financial information for the three and six months ended June 30, 2026 and 2025, including the results of operations for Intelerad as if the Intelerad acquisition had been completed on January 1, 2025, is as follows.


	For the three months ended June 30				For the six months ended June 30
	2026		2025		2026		2025
Total revenues	$	5,295	$	5,065	$	10,478	$	9,898
Net income attributable to GE HealthCare	567		462		971		981

Table of Contents

The unaudited supplemental pro forma consolidated financial information was prepared using the acquisition method of accounting and was based on the historical financial information of Intelerad. In order to reflect the occurrence of the acquisition on January 1, 2025, the unaudited supplemental pro forma financial information includes adjustments to reflect the following: (i) incremental amortization expense based on the current preliminary fair values of the identifiable intangible assets; (ii) the additional interest expense associated with the issuance of debt to finance the acquisition; and (iii) the reclassification of transaction and other acquisition-related costs incurred during the three and six months ended June 30, 2026, to the three and six months ended June 30, 2025. The unaudited supplemental pro forma financial information is not necessarily indicative of what the consolidated results of operations would have been had the acquisition been completed on January 1, 2025. In addition, the unaudited pro forma financial information is not a projection of future results of operations of the combined company, nor does it reflect the expected realization of any synergies or cost savings associated with the acquisition.

icometrix

On November 7, 2025, the Company acquired 100% of the stock of icometrix NV (“icometrix”) for approximately $98 million of upfront payment, net of cash acquired and potential earn-out payments up to $35 million based on sales targets over two years. icometrix is focused on providing AI-powered brain imaging analysis for neurological disorders such as Alzheimer’s disease. We are in the process of integrating the icometrix platform with our MRI systems. icometrix is included in the Company’s AIS segment.

The preliminary purchase price allocation resulted in goodwill of $74 million, intangible assets of $34 million, and deferred tax liabilities of $9 million. Purchase price allocations are based on preliminary valuations. Our estimates and assumptions are subject to change within the measurement period. The goodwill associated with the acquired business is non-deductible for tax purposes.

Nihon Medi-Physics

On March 31, 2025, the Company acquired the remaining 50% interest in Nihon Medi-Physics Co., Ltd. (“NMP”) from joint venture partner Sumitomo Chemical for net cash consideration of $271 million. NMP is a leading pharmaceutical manufacturer in Japan, focused on radiopharmaceuticals, which are used to enable clinical images across neurology, cardiology, and oncology procedures, as well as nonclinical and clinical development of radiotracers and theranostics research. Their product portfolio includes several GE HealthCare radiopharmaceuticals. NMP is included in the Company’s PDx segment.

On March 31, 2025, the fair value of the Company’s existing 50% interest in NMP was determined to be $301 million based on the cash consideration exchanged for acquiring the remaining 50% equity interest. The carrying value of our 50% interest was $204 million. The Company recognized a net gain of $97 million resulting from this remeasurement to fair value. This gain included the reclassification of certain amounts related to the Company’s 50% interest out of Accumulated other comprehensive income (loss) – net (“AOCI”) including foreign currency translation gains of $63 million and losses related to a defined benefit pension plan of $8 million. The net gain from this remeasurement was recorded in Other (income) expense – net in the Company’s Condensed Consolidated Statements of Income for the six months ended June 30, 2025.

The following table provides a summary of the purchase price consideration transferred for the acquisition of NMP.


	Purchase consideration
Cash consideration, net of cash acquired	$	271
Fair value of previously held interest in NMP	301
Fair value of contingent consideration	5
Total allocable purchase price	$	577

The fair values of the assets and liabilities assumed in connection with the acquisition of NMP, which were finalized in the first quarter of 2026 without material adjustment, are as follows.


	Purchase price allocation
Receivables	$	53
Inventories	9
All other current assets(1)	35
Property, plant, and equipment	239
Goodwill	221
Other intangible assets	235
All other non-current assets	39
Deferred income taxes	(80)
All other non-current liabilities	(145)
Other(2)	(29)
Total net assets post acquisition	$	577

(1) All other current assets includes $35 million of indemnification assets, with the underlying indemnified liabilities recorded in All other non-current liabilities.

(2) Other includes Accounts payable, All other current liabilities, and Current compensation and benefits.

Table of Contents

Property, plant, and equipment is mostly comprised of land, buildings, equipment (including machinery, furniture, and fixtures) and construction in process. The fair value of property, plant, and equipment was determined using a market participant approach.

Other intangibles relate to $235 million of definite-lived intangible assets, primarily consisting of developed product market authorization rights and customer relationships. The acquired definite-lived intangibles are being amortized over a weighted-average estimated useful life of approximately 13 years. The estimated fair value of intangibles was determined using the income approach.

The goodwill associated with NMP, recorded within the PDx segment, is non-deductible for tax purposes and is attributed to expected synergies with NMP’s existing assets and workforce that are expected to allow the Company greater access and growth in the Japan market.

Included in All other non-current liabilities are asset retirement obligations and decommissioning liabilities of $124 million, which were assumed in the transaction.

NMP has a defined benefit pension plan which has pension assets of $71 million and pension liabilities of $33 million, a net asset of $38 million, which we acquired in the transaction and is included in All other non-current assets.

Deferred income tax liabilities include the expected U.S. federal, state, and foreign tax consequences associated with temporary differences between the fair values of the assets acquired and liabilities assumed and the respective tax basis.

If the acquisition of NMP had taken place as of the beginning of 2024, consolidated revenues and earnings would not have been significantly different than reported amounts.

GOODWILL.

As discussed in Note 3, “Segment Information,” in the second quarter of 2026, the Company combined its Imaging and AVS businesses into a new operating and reportable segment, AIS. Accordingly, we combined the historical Imaging and AVS goodwill balances into the newly formed AIS segment.

We assess the possibility that a reporting unit’s fair value has been reduced below its carrying amount due to the occurrence of events or circumstances between annual impairment testing dates. In connection with the change in reportable segments in the second quarter of 2026, the Company evaluated the goodwill of our reporting units within the AIS segment for impairment before and after the segment realignment and we did not identify any events or circumstances that would require an interim impairment test. In addition, with respect to goodwill within the PDx and PCS segments, we did not identify any events or circumstances that required an interim impairment test since the last annual impairment testing date. Future changes in operating results, market conditions, or other relevant assumptions could affect this assessment. Should the Company identify future indicators of goodwill impairment, it may be required to conduct an interim impairment test that could result in a goodwill impairment charge.


	AIS		PDx		PCS		Total



Balance at December 31, 2025	$	8,702	$	2,745	$	2,041	$	13,489
Acquisitions(1)	1,629		—		—		1,629
Foreign currency exchange and other	(14)		(7)		(2)		(23)
Balance at June 30, 2026	$	10,317	$	2,738	$	2,040	$	15,095

(1) Includes the purchase of Intelerad recorded within our AIS segment, as described above.

OTHER INTANGIBLE ASSETS.



	As of June 30, 2026						As of December 31, 2025
	Gross Carrying Amount		Accumulated Amortization		Net		Gross Carrying Amount		Accumulated Amortization		Net
Definite-lived assets
Customer-related	$	390	$	(55)	$	335	$	279	$	(43)	$	236
Patents and technology	3,379		(2,213)		1,167		2,698		(2,128)		570
Capitalized software	1,769		(1,513)		256		1,703		(1,470)		233
Trademarks and other	97		(35)		62		47		(31)		15
Total definite-lived assets	5,635		(3,816)		1,820		4,727		(3,672)		1,055
Indefinite-lived assets(1)	75		—		75		75		—		75
Total other intangible assets	$	5,710	$	(3,816)	$	1,894	$	4,802	$	(3,672)	$	1,130

(1) Indefinite-lived intangible assets relate to acquired in-process research and development prior to project completion and are not amortized.

Table of Contents

Amortization expense was $84 million and $75 million for the three months ended June 30, 2026 and 2025, respectively, and $159 million and $146 million for the six months ended June 30, 2026 and 2025, respectively.

NOTE 8. BORROWINGS

The Company’s borrowings include the senior unsecured notes and credit agreements detailed below.

Senior Unsecured Notes

As of June 30, 2026, the Company’s borrowings include $9,500 million aggregate principal amount of senior unsecured notes in nine series with maturity dates ranging from 2027 through 2052.

Credit Facilities

In the first quarter of 2026, the Company terminated its existing $500 million 364-day senior unsecured revolving credit facility and replaced it with a new $500 million 364-day senior unsecured revolving credit facility with terms that are substantially similar to those of the terminated facility.

The Company has credit agreements providing for:

a five-year senior unsecured revolving credit facility in an aggregate committed amount of $3,000 million, maturing on March 27, 2030;
a 364-day senior unsecured revolving credit facility in an aggregate committed amount of $500 million, maturing on February 25, 2027; and
a three-year senior unsecured delayed draw term loan credit facility in an aggregate principal amount of $650 million, maturing on March 16, 2029 (the “Delayed Draw Term Loan Facility” and, together with the five-year senior unsecured revolving credit facility and the 364-day senior unsecured revolving credit facility, the “Credit Facilities”).

In the first quarter of 2026, in connection with the acquisition of Intelerad, the Company borrowed $500 million under the 364-day senior unsecured revolving credit facility and subsequently completed a $650 million drawdown of the Delayed Draw Term Loan Facility, which had aggregate lender commitments of $750 million. The $100 million of unused lender commitments for the Delayed Draw Term Loan Facility automatically terminated upon completion of the drawdown. Immediately following the acquisition, the Company repaid $500 million under the 364-day senior unsecured revolving credit facility. Refer to Note 7, “Acquisitions, Goodwill, and Other Intangible Assets” for more information on our Intelerad acquisition.

There were no outstanding amounts under the five-year senior unsecured revolving credit facility or the 364-day senior unsecured revolving credit facility as of June 30, 2026 and December 31, 2025, respectively.


Borrowings Composition	As of
	June 30, 2026		December 31, 2025
5.650% senior notes due November 15, 2027	$	1,750	$	1,750
4.150% senior notes due December 15, 2028	600		600
4.800% senior notes due August 14, 2029	1,000		1,000
5.857% senior notes due March 15, 2030	1,250		1,250
4.800% senior notes due January 15, 2031	650		650
5.905% senior notes due November 22, 2032	1,750		1,750
5.500% senior notes due June 15, 2035	850		850
4.950% senior notes due December 15, 2035	650		650
6.377% senior notes due November 22, 2052	1,000		1,000
Floating rate Delayed Draw Term Loan Facility due March 16, 2029	650		—
Floating rate Term Loan Facility due January 2, 2026(1)	—		500
Other	13		24
Total principal debt issued	10,163		10,024
Less: Unamortized debt issuance costs and discounts	44		49
Add: Cumulative basis adjustment for fair value hedges	(25)		27
Total borrowings	10,093		10,003
Less: Short-term borrowings(2)	2		508
Long-term borrowings	$	10,091	$	9,495

(1) In the first quarter of 2026, the Company repaid $500 million of the remaining Term Loan Facility upon maturity.

(2) Short-term borrowings as of June 30, 2026 and December 31, 2025 includes $2 million and $502 million, respectively, related to the current portion of our long-term borrowings, net of unamortized debt issuance costs and discounts.

Table of Contents

See Note 12, “Financial Instruments and Fair Value Measurements” for further information about borrowings and associated derivatives contracts.

LETTERS OF CREDIT, GUARANTEES, AND OTHER COMMITMENTS.

As of June 30, 2026 and December 31, 2025, the Company had bank guarantees and surety bonds of approximately $1,189 million and $1,149 million, respectively, related to certain commercial contracts. Additionally, we have issued approximately $20 million and $22 million of guarantees as of June 30, 2026 and December 31, 2025, respectively, primarily related to residual value and credit guarantees on equipment sold to third-party finance companies. Our Condensed Consolidated Statements of Financial Position reflect a liability of $3 million as of both June 30, 2026 and December 31, 2025 related to these guarantees. For credit-related guarantees, we estimate our expected credit losses related to off-balance sheet credit exposure consistent with the method used to estimate the allowance for credit losses on financial assets held at amortized cost.

NOTE 9. POSTRETIREMENT BENEFIT PLANS

We sponsor a number of pension and retiree health and life insurance benefit plans that we present in three categories: U.S. Plans, International Plans, and Other Postretirement Plans (“OPEB Plans”). Refer to Note 10, “Postretirement Benefit Plans” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025 for further information. Pension plans with pension assets or obligations less than $50 million are not included in the results below.


Components of Expense (Income)
	U.S. Plans				International Plans				OPEB Plans

For the three months ended June 30,	2026		2025		2026		2025		2026		2025
Service cost – Operating	$	1	$	1	$	5	$	5	$	1	$	1
Interest cost	241		249		39		38		11		13
Expected return on plan assets	(275)		(287)		(40)		(38)		—		—
Amortization of net loss (gain)	—		(20)		6		5		(14)		(15)
Amortization of prior service cost (credit)	(3)		(3)		(1)		(1)		(18)		(20)

Special termination cost	—		1		—		—		—		—
Non-operating	$	(37)	$	(59)	$	5	$	4	$	(21)	$	(21)
Net periodic expense (income)	$	(36)	$	(58)	$	9	$	10	$	(20)	$	(20)



	U.S. Plans				International Plans					OPEB Plans
For the six months ended June 30,	2026		2025			2026		2025			2026		2025
Service cost – Operating	$	2	$	2		$	9	$	10		$	3	$	3
Interest cost	481		497			79		74			22		26
Expected return on plan assets	(550)		(573)			(81)		(74)			—		—
Amortization of net loss (gain)	—		(40)			12		10			(29)		(30)
Amortization of prior service cost (credit)	(5)		(5)			(1)		(1)			(35)		(40)


Special termination cost	—		2			—		—			—		1
Non-operating	$	(74)	$	(119)		$	9	$	9		$	(42)	$	(43)
Net periodic expense (income)	$	(72)	$	(117)		$	18	$	19		$	(39)	$	(40)

In the six months ended June 30, 2026, the Company made cash payments totaling $90 million to its U.S. Plans, $19 million to its International Plans, and $62 million to its OPEB Plans. As of June 30, 2026, the Company expects to make total cash contributions of approximately $350 million to these plans in 2026. The Company funds annually, at a minimum, the statutorily required minimum amount for our qualified plans. Non-qualified plans are unfunded and we pay benefits from our cash on hand.

Defined Contribution Plan

GE HealthCare sponsors a defined contribution plan for its eligible U.S. employees. Expenses associated with our employees’ participation in GE HealthCare’s defined contribution plan were $39 million for both the three months ended June 30, 2026 and 2025, and $87 million and $83 million for the six months ended June 30, 2026 and 2025, respectively.

NOTE 10. INCOME TAXES

Our effective income tax rate was 17.2% and 18.4% for the three months ended June 30, 2026 and 2025, respectively, and 17.8% and 16.6% for the six months ended June 30, 2026 and 2025, respectively.

Table of Contents

The tax rate for the three and six months ended June 30, 2026 is lower than the U.S. statutory rate primarily due to the use of tax attributes and foreign-derived deduction eligible income benefits, reconciling adjustments to recorded tax account balances, and research and development (“R&D”) benefits, partially offset by withholding taxes, geographic earnings mix, and state taxes.

The tax rate for the three months ended June 30, 2025 is lower than the U.S. statutory rate primarily due to the use of tax attributes and R&D benefits, partially offset by withholding taxes, geographic earnings mix, and state taxes. The tax rate for the six months ended June 30, 2025 is lower than the U.S. statutory rate primarily due to foreign income tax reserve releases, the use of tax attributes, the nontaxable remeasurement gain that was recorded in connection with the NMP acquisition, and R&D benefits, partially offset by withholding taxes, geographic earnings mix, and state taxes.

The Company is currently being audited, or remains subject to audit, in a number of jurisdictions for the tax years 2004-2024, including China, France, Germany, India, Japan, Norway, the United Kingdom, and the United States.

NOTE 11. SHAREHOLDERS' EQUITY

ACCUMULATED OTHER COMPREHENSIVE INCOME (LOSS) – NET.

Changes in AOCI by component were as follows.


	For the three months ended June 30, 2026
	Currency translation adjustments(1)		Pension and Other Postretirement Plans		Cash flow hedges		Total AOCI
March 31, 2026	$	(1,566)	$	147	$	20	$	(1,398)
Other comprehensive income (loss) before reclassifications – net of taxes of $8, $—, and $(4)	(71)		1		18		(52)
Reclassifications from AOCI – net of taxes(2) of $—, $6, and $1	—		(19)		(10)		(29)
Other comprehensive income (loss)	(71)		(18)		8		(80)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	1		—		—		1
June 30, 2026	$	(1,637)	$	129	$	28	$	(1,480)


	For the three months ended June 30, 2025
	Currency translation adjustments(1)		Pension and Other Postretirement Plans		Cash flow hedges		Total AOCI
March 31, 2025	$	(1,717)	$	507	$	10	$	(1,199)
Other comprehensive income (loss) before reclassifications – net of taxes of $44, $11, and $10	221		(38)		(37)		146
Reclassifications from AOCI – net of taxes(2) of $—, $12, and $1	—		(41)		4		(37)
Other comprehensive income (loss)	221		(79)		(33)		108
Less: Other comprehensive income (loss) attributable to noncontrolling interests	—		—		—		—
June 30, 2025	$	(1,495)	$	428	$	(23)	$	(1,090)


	For the six months ended June 30, 2026
	Currency translation adjustments(1)		Pension and Other Postretirement Plans		Cash flow hedges		Total AOCI
December 31, 2025	$	(1,548)	$	158	$	3	$	(1,388)
Other comprehensive income (loss) before reclassifications – net of taxes of $(17), $(3), and $(10)	(97)		13		41		(42)
Reclassifications from AOCI – net of taxes(2) of $—, $12, and $1	—		(41)		(16)		(57)
Other comprehensive income (loss)	(97)		(28)		25		(100)
Less: Other comprehensive income (loss) attributable to noncontrolling interests	(8)		—		—		(8)
June 30, 2026	$	(1,637)	$	129	$	28	$	(1,480)

Table of Contents


	For the six months ended June 30, 2025
	Currency translation adjustments(1)		Pension and Other Postretirement Plans		Cash flow hedges		Total AOCI
December 31, 2024	$	(1,973)	$	576	$	18	$	(1,379)
Other comprehensive income (loss) before reclassifications – net of taxes of $59, $16, and $14	415		(58)		(48)		308
Reclassifications from AOCI – net of taxes(2)(3) of $—, $28, and $—	63		(90)		7		(20)
Other comprehensive income (loss)	478		(148)		(41)		288
Less: Other comprehensive income (loss) attributable to noncontrolling interests	—		—		—		—
June 30, 2025	$	(1,495)	$	428	$	(23)	$	(1,090)

(1) The amount of Currency translation adjustments recognized in Other comprehensive income (loss) (“OCI”) included net gains (losses) relating to net investment hedges, as further discussed in Note 12, “Financial Instruments and Fair Value Measurements.”

(2) Reclassifications from AOCI into earnings for Pension and Other Postretirement Plans are recognized within Non-operating benefit (income) costs, while Cash flow hedges are recognized within Cost of products and Cost of services in our Condensed Consolidated Statements of Income.

(3) Includes net of tax impact of $63 million of gains to Currency translation adjustments and $8 million of losses to Pension and Other Postretirement Plans related to the derecognition of the prior NMP equity method investment. Refer to Note 7, “Acquisitions, Goodwill, and Other Intangible Assets” for additional information on the NMP acquisition.

SHARE REPURCHASES.

On April 30, 2025, our Board of Directors authorized a share repurchase program (the “repurchase program”) for up to $1,000 million of our common stock. The repurchase program does not have an expiration date, does not obligate the Company to acquire any particular amount of common stock, and may be suspended or terminated at any time at the Company's discretion. During the three and six months ended June 30, 2026, we repurchased 3.3 million shares and 4.7 million shares, respectively, for total consideration of approximately $200 million and $300 million, respectively. During the three months ended June 30, 2025, we repurchased 1.4 million shares for total consideration of approximately $100 million. As of June 30, 2026, we had $500 million available under the repurchase program authorization.

NOTE 12. FINANCIAL INSTRUMENTS AND FAIR VALUE MEASUREMENTS

DERIVATIVES AND HEDGING.

Our primary objective in executing and holding derivative contracts is to reduce the volatility of earnings and cash flows associated with risks related to foreign currency exchange rates, interest rates, and equity prices. These derivative contracts reduce, but do not entirely eliminate, the aforementioned risks. Our policy is to use derivative contracts solely for managing risks and not for speculative purposes.

Cash Flow Hedges

For derivative instruments designated as cash flow hedges, changes in the fair value of designated hedging instruments are initially recorded as a component of AOCI and subsequently reclassified to earnings in the period in which the hedged transaction affects earnings and to the same financial statement line item impacted by the hedged transaction. As of June 30, 2026, we expect to reclassify $42 million of pre-tax net deferred gains associated with designated cash flow hedges to earnings in the next 12 months, contemporaneously with the impact on earnings of the related hedged transactions.

Within the Condensed Consolidated Statements of Cash Flows, cash flows associated with derivatives designated as cash flow hedges are recorded in All other operating activities – net.

Net Investment Hedges

We use cross-currency interest rate swaps and foreign currency forward contracts in combination with foreign currency option contracts to hedge the foreign currency risk associated with our net investment in foreign operations. As of June 30, 2026, these contracts were designated as hedges of our net investment in foreign operations, primarily in Euro and Chinese Renminbi currencies.

Within the Condensed Consolidated Statements of Cash Flows, cash flows associated with derivatives designated as net investment hedges are recorded in All other investing activities – net and cash flows from the periodic interest settlements on the cross-currency swaps are recorded in All other operating activities – net.

Table of Contents

Fair Value Hedges

We use interest rate swaps to hedge the interest rate risk on our fixed rate borrowings. These derivatives are designated as fair value hedges to hedge the changes in fair value due to benchmark interest rate risk of specific designated cash flows of our senior unsecured notes.

We record the changes in fair value on these swap contracts in Interest and other financial charges – net in our Condensed Consolidated Statements of Income, the same line item where the offsetting change in the fair value of the designated cash flows of the senior unsecured note is recorded as a basis adjustment.

Within the Condensed Consolidated Statements of Cash Flows, cash flows for the periodic interest settlements on the interest rate swaps are recorded in All other operating activities – net.

Derivatives Not Designated as Hedging Instruments

We also execute derivative instruments, such as foreign currency forward contracts and equity-linked total return swaps, which are not designated as qualifying hedges. These derivatives serve as economic hedges of foreign currency exchange rate and equity price risks. We also identify and record foreign currency-related features in our purchase or sales contracts where the currency is not the local or functional currency of any substantive party to the contract as embedded derivatives.

The changes in fair value of derivatives not designated as qualifying hedge transactions are recorded in Cost of products, Cost of services, Selling, general, and administrative (“SG&A”), and Other (income) expense – net in the Condensed Consolidated Statements of Income based on the nature of the underlying hedged transaction. Changes in fair value of embedded derivatives are recognized in Other (income) expense – net in the Condensed Consolidated Statements of Income.

Within the Condensed Consolidated Statements of Cash Flows, cash flows associated with derivatives not designated but used as economic hedges are recorded, based on the nature of the underlying hedged transaction, in All other operating activities – net and All other investing activities – net, and cash flows related to embedded derivatives are recorded in All other operating activities – net.

The following table presents the gross fair values of our outstanding derivative instruments.


Fair Value of Derivatives	June 30, 2026						December 31, 2025
	Gross Notional		Fair Value – Assets		Fair Value – Liabilities		Gross Notional		Fair Value – Assets		Fair Value – Liabilities
Foreign currency forward contracts	$	1,636	$	82	$	7	$	1,508	$	52	$	23
Derivatives accounted for as cash flow hedges	1,636		82		7		1,508		52		23
Cross-currency swaps	3,990		68		70		4,115		51		135
Foreign currency forward and options contracts	2,628		52		38		2,581		50		37
Derivatives accounted for as net investment hedges	6,618		120		109		6,697		101		172
Interest rate swaps	2,700		—		25		2,700		28		—
Derivatives accounted for as fair value hedges	2,700		—		25		2,700		28		—
Foreign currency forward contracts	5,468		10		24		4,761		20		7
Other derivatives(1)	324		11		3		320		56		5



Derivatives not designated as hedging instruments	5,792		21		27		5,081		76		12
Total derivatives	$	16,746	$	222	$	167	$	15,986	$	256	$	207

(1) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts.

The following table presents amounts recorded in Long-term borrowings in the Condensed Consolidated Statements of Financial Position related to cumulative basis adjustment for fair value hedges.


	June 30, 2026				December 31, 2025
	Carrying amount		Cumulative basis adjustment included in the carrying amount		Carrying amount		Cumulative basis adjustment included in the carrying amount
Long-term borrowings designated as fair value hedges	$	2,670	$	(25)	$	2,722	$	27

Under the master arrangements with the respective counterparties to our derivative contracts, in certain circumstances and subject to applicable requirements, we are allowed to net settle transactions with a single net amount payable by one party to the other. However, we have elected to present the derivative assets and derivative liabilities on a gross basis in our Condensed Consolidated Statements of Financial Position and in the table above.

Table of Contents

As of June 30, 2026 and December 31, 2025, the potential effect of rights of offset associated with the derivative contracts would be an offset to both assets and liabilities by $98 million and $107 million, respectively.

The table below presents the pre-tax gains (losses) recognized in OCI associated with the Company’s cash flow and net investment hedges.


Pre-tax Gains (Losses) Recognized in OCI Related to Cash Flow and Net Investment Hedges
	For the three months ended June 30				For the six months ended June 30
	2026		2025		2026		2025
Cash flow hedges	$	22	$	(47)	$	51	$	(62)
Net investment hedges(1)	(35)		(189)		72		(254)

(1) Amounts recognized in OCI for excluded components for the periods presented were immaterial.

The tables below present the gains (losses) on our derivative financial instruments and hedging activity in the Condensed Consolidated Statements of Income.


Derivative Financial Instruments and Hedging Activity	For the three months ended June 30, 2026
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(4)

Foreign currency forward contracts	$	9	$	2	$	—	$	—	$	—
Effects of cash flow hedges	9		2		—		—		—
Cross-currency swaps	—		—		—		13		—
Foreign currency forward and options contracts	—		—		—		6		—
Effects of net investment hedges(1)	—		—		—		19		—

Interest rate swaps(2)	—		—		—		(34)		—
Debt basis adjustment on Long-term borrowings	—		—		—		34		—

Effects of fair value hedges	—		—		—		1		—
Foreign currency forward contracts	10		3		—		—		—



Other derivatives(3)	—		—		7		—		22
Effects of derivatives not designated as hedging instruments	10		3		7		—		23























	For the three months ended June 30, 2025
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(4)

Foreign currency forward contracts	$	(3)	$	(1)	$	—	$	—	$	—
Effects of cash flow hedges	(3)		(1)		—		—		—
Cross-currency swaps	—		—		—		6		—
Foreign currency forward and option contracts	—		—		—		5		—
Effects of net investment hedges(1)	—		—		—		11		—

Interest rate swaps(2)	—		—		—		24		—
Debt basis adjustment on Long-term borrowings	—		—		—		(28)		—

Effects of fair value hedges	—		—		—		(4)		—
Foreign currency forward contracts	44		12		—		—		(1)
Other derivatives(3)	—		—		4		—		6
Effects of derivatives not designated as hedging instruments	44		12		4		—		5

Table of Contents


Derivative Financial Instruments and Hedging Activity	For the six months ended June 30, 2026
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(4)

Foreign currency forward contracts	$	14	$	3	$	—	$	—	$	—
Effects of cash flow hedges	14		3		—		—		—
Cross-currency swaps	—		—		—		25		—
Foreign currency forward and options contracts	—		—		—		11		—
Effects of net investment hedges(1)	—		—		—		36		—

Interest rate swaps(2)	—		—		—		(51)		—
Debt basis adjustment on Long-term borrowings	—		—		—		53		—

Effects of fair value hedges	—		—		—		2		—
Foreign currency forward contracts	23		6		—		—		—



Other derivatives(3)	—		—		4		—		16
Effects of derivatives not designated as hedging instruments	23		6		4		—		16























	For the six months ended June 30, 2025
	Cost of products		Cost of services		SG&A		Interest and other financial charges – net		Other(4)

Foreign currency forward contracts	$	(5)	$	(1)	$	—	$	—	$	—
Effects of cash flow hedges	(5)		(1)		—		—		—
Cross-currency swaps	—		—		—		14		—
Foreign currency forward and option contracts	—		—		—		8		—
Effects of net investment hedges(1)	—		—		—		22		—

Interest rate swaps(2)	—		—		—		80		—
Debt basis adjustment on Long-term borrowings	—		—		—		(88)		—

Effects of fair value hedges	—		—		—		(8)		—
Foreign currency forward contracts	59		16		—		—		(1)
Other derivatives(3)	—		—		1		—		(9)
Effects of derivatives not designated as hedging instruments	59		16		1		—		(10)

(1) Changes in fair value related to components other than the spot rate are excluded from effectiveness testing for the three and six months ended June 30, 2026 and 2025.

(2) Amount includes interest income (expense) on interest rate derivatives of $1 million and $(4) million for the three months ended June 30, 2026 and 2025, respectively, and $2 million and $(8) million for the six months ended June 30, 2026 and 2025, respectively.

(3) Other derivatives are comprised of embedded derivatives and derivatives related to equity contracts.

(4) Amounts are inclusive of gains (losses) in Other (income) expense – net in the Condensed Consolidated Statements of Income.

Table of Contents

FAIR VALUE MEASUREMENTS.

The following table represents assets and liabilities that are recorded and measured at fair value on a recurring basis.


Fair Value of Assets and Liabilities Measured on a Recurring Basis
	As of June 30, 2026								As of December 31, 2025
	Level 1		Level 2		Level 3		Total		Level 1		Level 2		Level 3		Total
Assets:
Money market funds	$	—	$	309	$	—	$	309	$	—	$	399	$	—	$	399
Investment securities	52		—		30		82		47		—		30		77
Derivatives	—		222		—		222		—		256		—		256
Liabilities:
Derivatives	—		167		—		167		—		207		—		207
Contingent consideration	—		—		20		20		—		—		30		30

Cash equivalents

As of June 30, 2026 and December 31, 2025, Cash, cash equivalents, and restricted cash of $2,105 million and $4,512 million, respectively, included money market funds of $309 million and $399 million, and other cash equivalents of $950 million and $3,046 million, respectively. The carrying values of the other cash equivalents approximates the fair value due to their short maturities and are valued using Level 1 or Level 2 inputs. Refer to Note 16, “Supplemental Financial Information” for further information.

Derivatives

Derivatives are measured at fair value using a discounted cash flow method or option models using interest rates, foreign exchange spot and forward rates and yield curves observable at commonly quoted intervals, implied volatilities, and credit spreads as key inputs. Unobservable inputs relate to our own credit risk which is not significant to the overall measurement of fair value.

Contingent consideration

Contingent consideration is recorded at fair value based on estimates of future cash flows in connection with business acquisitions. As the valuation of these liabilities is based on inputs that are less observable or not observable in the market, the determination of fair value is classified within Level 3 of the fair value hierarchy.

Non-recurring fair value measurements

Changes in fair value measurements of assets and liabilities measured at fair value on a non-recurring basis, such as equity method investments, equity investments without readily determinable fair value, financing receivables, and long-lived assets, were not material for the six months ended June 30, 2026 and 2025, with the exception of the gain on fair value measurement of the NMP equity method investment as described in Note 7, “Acquisitions, Goodwill, and Other Intangible Assets.”

Fair value of other financial instruments

The estimated fair value of borrowings as of June 30, 2026 and December 31, 2025 was $10,495 million and $10,545 million, respectively, compared to a carrying value (which only includes a reduction for unamortized debt issuance costs and discounts and cumulative basis adjustment) of $10,093 million and $10,003 million, respectively. The fair value of our borrowings includes accrued interest and is determined based on observable and quoted prices and spreads of comparable debt and benchmark securities and is considered Level 2 in the fair value hierarchy. See Note 8, “Borrowings” and Note 16, “Supplemental Financial Information” for further information.

NOTE 13. COMMITMENTS, GUARANTEES, PRODUCT WARRANTIES, AND OTHER LOSS CONTINGENCIES

GUARANTEES.

The Company has off-balance sheet credit exposure through standby letters of credit, bank guarantees, bid bonds, and surety bonds. See Note 8, “Borrowings” for further information.

PRODUCT WARRANTIES.

We provide warranty coverage to our customers as part of customary practices in the market to provide assurance that the products we sell comply with agreed-upon specifications. We provide estimated product warranty expenses when we sell the related products. Warranty accruals are estimates that are based on the best available information, mostly historical claims experience, therefore claims costs may differ from amounts provided. An analysis of changes in the liability for product warranties follows.

Table of Contents



	For the six months ended June 30
	2026		2025
Balance at beginning of period	$	169	$	168
Current-year provisions	104		113
Expenditures	(95)		(120)
Foreign currency exchange and other	(1)		6
Balance at end of period	$	176	$	166

Product warranties are recognized within All other current liabilities in the Condensed Consolidated Statements of Financial Position.

LEGAL MATTERS.

In the normal course of our business, we are involved from time to time in various arbitrations; class actions; commercial, intellectual property, and product liability litigation; government investigations; investigations by competition/antitrust authorities; and other legal, regulatory, or governmental actions, including the significant matter described below that could have a material impact on our results of operations and cash flows. In many proceedings, including the specific matter described below, it is inherently difficult to determine whether any loss is probable or even reasonably possible or to estimate the size or range of the possible loss, and accruals for legal matters are not recorded until a loss for a particular matter is considered probable and reasonably estimable. Given the nature of legal matters and the complexities involved, it is often difficult to predict and determine a meaningful estimate of loss or range of loss until we know, among other factors, the particular claims involved, the likelihood of success of our defenses to those claims, the damages or other relief sought, how discovery or other procedural considerations will affect the outcome, the settlement posture of other parties, and other factors that may have a material effect on the outcome. For such matters, unless otherwise specified, we do not believe it is possible to provide a meaningful estimate of loss at this time. Moreover, it is not uncommon for legal matters to be resolved over many years, during which time relevant developments and new information must be continuously evaluated.

Contracts with Iraqi Ministry of Health

In 2017, a number of U.S. Service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia (the “District Court”) against a number of pharmaceutical and medical device companies, including GE HealthCare and certain affiliates, alleging that the defendants violated the U.S. Anti-Terrorism Act. The complaint seeks monetary relief and alleges that the defendants provided funding for an Iraqi terrorist organization through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health. In July 2020, the District Court granted defendants’ motions to dismiss and dismissed all of the plaintiffs’ claims. In January 2022, a panel of the U.S. Court of Appeals for the District of Columbia Circuit (the “Court of Appeals”) reversed the District Court’s decision. In February 2022, the defendants requested review of the decision by all the judges on the Court of Appeals (an “en banc” review). In February 2023, the Court of Appeals denied this request. In June 2023, defendants petitioned the Supreme Court to review the Court of Appeals’ decision. In June 2024, the Supreme Court vacated the Court of Appeals’ decision and remanded the case to the Court of Appeals for further consideration. In January 2026, the Court of Appeals reversed the District Court’s decision to dismiss the complaint and remanded the case for further proceedings. In April 2026, the Court of Appeals denied defendants’ request for an en banc review of the Court of Appeals’ decision. The parties are now in the discovery process.

INDEMNITIES.

In connection with the Tax Matters Agreement with GE as described in Note 19, “Related Parties and Transition Services Agreement” in our Annual Report on Form 10-K for the fiscal year ended December 31, 2025, we have been informed that the Internal Revenue Service (“IRS”) may assert a material amount of additional taxes related to an ongoing IRS audit of the GE consolidated U.S. income tax returns, in which we are included, for the years 2016-2020. Any tax obligations would be allocated among the Company and GE, in accordance with the Tax Matters Agreement. A final resolution of this matter could be time-consuming and is not likely within the next 12 months. An unfavorable resolution of this matter and related allocation of additional tax liability, which is not reasonably estimable at this time, could result in additional material indemnification obligations due to GE for which we have not accrued a liability.

TARIFF REFUND CLAIMS.

In February 2026, the U.S. Supreme Court ruled that the International Emergency Economic Powers Act (“IEEPA”) does not authorize the President to impose tariffs thereunder. In April 2026, U.S. Customs and Border Protection announced a new administrative process for importers to obtain refunds of certain tariffs imposed under IEEPA.

Table of Contents

The Company has submitted eligible refund claims through the established refund process and recognizes a receivable for anticipated IEEPA tariff refunds when management concludes that recovery of previously recognized tariff costs is probable and the amount of the recovery can be reasonably estimated. As of June 30, 2026, the Company received $107 million of refunds and recorded a $38 million receivable for submitted claims not yet reimbursed. The receivable is included within Receivables - net of allowances in the Condensed Consolidated Statements of Financial Position. In the second quarter of 2026, we recognized pre-tax benefits from tariff refunds of $106 million related to tariffs incurred in 2025 and $23 million related to tariffs incurred in 2026, all of which are recorded within Cost of products sold and Cost of services sold in the Condensed Consolidated Statements of Income.

While the Company believes recovery of the submitted claims is probable and estimable, the ultimate amount and timing of recovery remain subject to validation and administrative processing procedures, as well as potential legal, regulatory, and administrative developments. Accordingly, actual recoveries could differ from recorded amounts.

NOTE 14. RESTRUCTURING ACTIVITIES

Restructuring activities are essential to optimize the business operating model for GE HealthCare and mostly involve workforce reductions, organizational realignments, and revisions to our real estate footprint. Specifically, restructuring charges (gains) primarily include employee-related termination benefits associated with workforce reductions, facility exit costs, asset write-downs, and cease-use costs. Net expenses for restructuring are excluded from Segment EBIT.

Net expenses for restructuring initiatives committed to by management through June 30, 2026 are included in the table below.


	For the three months ended June 30				For the six months ended June 30
	2026		2025		2026		2025
Employee termination costs	$	25	$	12	$	68	$	32
Facility and other exit costs	2		1		5		2
Asset write-downs	—		5		3		6
Total restructuring activities – net	$	27	$	18	$	76	$	40

These restructuring initiatives are expected to result in additional expenses of approximately $38 million, to be incurred primarily over the next 12 months, substantially related to employee-related termination benefits and asset write-downs. Restructuring expenses (gains) are recognized within Cost of products, Cost of services, or SG&A, as appropriate, in the Condensed Consolidated Statements of Income.

Liabilities related to restructuring are recognized within Current compensation and benefits, All other current liabilities, Non-current compensation and benefits, and All other non-current liabilities in the Condensed Consolidated Statements of Financial Position. The activity related to our restructuring liabilities follows.


	Employee termination costs		Facility and other exit costs		Total




Balance at December 31, 2025	$	82	$	11	$	92
Charges and reserve adjustments	69		(2)		68
Payments and other adjustments	(48)		(2)		(51)
Balance at June 30, 2026	$	103	$	7	$	109

NOTE 15. EARNINGS PER SHARE

The numerator for both basic and diluted earnings per share (“EPS”) is Net income attributable to GE HealthCare. The denominator of basic EPS is the weighted-average number of shares outstanding during the period. The dilutive effect of outstanding stock options, restricted stock units, and performance share units is reflected in the denominator for diluted EPS using the treasury stock method.

Table of Contents


Earnings Per Share	For the three months ended June 30				For the six months ended June 30
(In millions, except per share amounts)	2026		2025		2026		2025
Numerator:
Net income	$	573	$	500	$	985	$	1,088
Net (income) loss attributable to noncontrolling interests	(13)		(14)		(35)		(39)
Net income attributable to GE HealthCare	$	561	$	486	$	950	$	1,049




Denominator:
Basic weighted-average shares outstanding	453		457		454		457
Dilutive effect of common stock equivalents	1		1		1		1
Diluted weighted-average shares outstanding	454		458		456		459

Basic earnings per share	$	1.24	$	1.06	$	2.09	$	2.30



Diluted earnings per share	1.24		1.06		2.08		2.29


Antidilutive securities(1)	5		5		4		4

(1) Diluted earnings per share excludes certain shares issuable under share-based compensation plans because the effect would have been antidilutive.

NOTE 16. SUPPLEMENTAL FINANCIAL INFORMATION

CASH, CASH EQUIVALENTS, AND RESTRICTED CASH.


	As of
	June 30, 2026		December 31, 2025
Cash and cash equivalents(1)	$	2,079	$	4,492
Short-term restricted cash	26		20
Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Financial Position	2,105		4,512
Long-term restricted cash(2)	3		3
Total Cash, cash equivalents, and restricted cash as presented in the Condensed Consolidated Statements of Cash Flows	$	2,108	$	4,515

(1) The decrease in Cash and cash equivalents was primarily due to the Intelerad acquisition. Refer to Note 7, “Acquisitions, Goodwill, and Other Intangible Assets” for further information.

(2) Long-term restricted cash is recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position.

INVENTORIES.


	As of
	June 30, 2026		December 31, 2025
Raw materials	$	1,063	$	1,002
Work in process	103		95
Finished goods	1,317		1,137
Inventories	$	2,483	$	2,234

Certain inventory items are long-term in nature and therefore have been recognized within All other non-current assets in the Condensed Consolidated Statements of Financial Position and are not reflected in the table above. See the supplemental table “All Other Non-Current Assets” for further information.

Table of Contents

PROPERTY, PLANT, AND EQUIPMENT – NET.


	As of
	June 30, 2026		December 31, 2025
Land and improvements	$	139	$	144
Buildings, structures, and related equipment	2,207		2,140
Machinery and equipment	2,872		2,872
Leasehold improvements and manufacturing plants under construction	582		574
Total property, plant, and equipment, at original cost	5,799		5,731
Accumulated depreciation	(3,044)		(3,049)
Operating lease ROU assets, net of amortization	391		410
Property, plant, and equipment – net	$	3,146	$	3,092

Depreciation expense related to Property, plant, and equipment – net, exclusive of operating lease ROU assets, was $76 million and $73 million for the three months ended June 30, 2026 and 2025, and $154 million and $138 million for the six months ended June 30, 2026 and 2025, respectively.

ALL OTHER ASSETS AND ALL OTHER LIABILITIES.


All Other Current Assets	As of
	June 30, 2026		December 31, 2025
Prepaid expenses and deferred costs	$	300	$	228
Financing receivables – net	92		95
Derivative instruments	125		169
Income tax receivables	164		154
Other(1)	111		81
All other current assets	$	793	$	726

(1) Other primarily consists of the current portion of capitalized cloud computing arrangement implementation costs, and indemnity assets associated with the separation agreements with GE. See the supplemental table “Capitalized Cloud Computing Arrangement Implementation Costs” for further information.


All Other Non-Current Assets	As of
	June 30, 2026		December 31, 2025
Prepaid pension asset	$	738	$	742
Equity method and other investments	362		351
Financing receivables – net	191		190
Derivative instruments	97		88
Long-term receivables – net	183		190
Inventories	127		121
Contract and other deferred assets	216		211
Capitalized cloud computing arrangement implementation costs(1)	221		200
Other(2)	120		112
All other non-current assets	$	2,254	$	2,205

(1) See the supplemental table “Capitalized Cloud Computing Arrangement Implementation Costs” for further information.

(2) Other primarily consists of indemnity assets associated with separation agreements with GE and income tax receivables.

Table of Contents


All Other Current Liabilities	As of
	June 30, 2026		December 31, 2025
Sales allowances and related liabilities	$	237	$	256
Income and indirect tax liabilities including uncertain tax positions	180		324
Product warranties	176		169
Accrued logistics and utilities	205		197
Operating lease liabilities	131		134
Derivative instruments	55		47
Interest payable on borrowings	91		100
Environmental and asset retirement obligations	11		11
Other(1)	344		348
All other current liabilities	$	1,429	$	1,587

(1) Other primarily consists of miscellaneous accrued costs, dividends payable, and contingent consideration liabilities.


All Other Non-Current Liabilities	As of
	June 30, 2026		December 31, 2025
Contract liabilities	$	857	$	803
Operating lease liabilities	263		284
Environmental and asset retirement obligations	441		413
Income and indirect tax liabilities including uncertain tax positions	232		156
Derivative instruments	113		160
Finance lease obligations	54		42
Sales allowances and related liabilities	26		23
Other(1)	149		178
All other non-current liabilities	$	2,133	$	2,061

(1) Other primarily consists of miscellaneous accrued costs, indemnity liabilities associated with separation agreements with GE, and contingent consideration liabilities.

CAPITALIZED CLOUD COMPUTING ARRANGEMENT IMPLEMENTATION COSTS.


	As of
	June 30, 2026		December 31, 2025
Capitalized implementation costs	$	340	$	249
Accumulated amortization	(68)		(49)
Total Capitalized cloud computing arrangement implementation costs, net	$	272	$	200

Capitalized cloud computing arrangement implementation costs are recognized within All other current assets and All other non-current assets in the Condensed Consolidated Statements of Financial Position. Amortization expense related to capitalized cloud computing arrangement implementation costs was $11 million and $4 million for the three months ended June 30, 2026 and 2025, respectively, and $19 million and $8 million for the six months ended June 30, 2026 and 2025, respectively.

SUPPLY CHAIN FINANCE PROGRAMS.

The Company participates in voluntary supply chain finance programs which provide participating suppliers the opportunity to sell their GE HealthCare receivables to third parties at the sole discretion of both the suppliers and the third parties. We evaluate supply chain finance programs to ensure the use of a third-party intermediary to settle our trade payables does not change the nature, existence, amount, or timing of our trade payables and does not provide the Company with any direct economic benefit. If any characteristics of the trade payables change or we receive a direct economic benefit, we reclassify the trade payables to borrowings. In connection with the supply chain finance programs, payment terms normally range from 30 to 180 days, depending on the underlying supplier agreements.

Included within Accounts payable in the Condensed Consolidated Statements of Financial Position as of June 30, 2026 and December 31, 2025 were $334 million and $360 million, respectively, of confirmed supplier invoices that are outstanding and subject to third-party programs.

Table of Contents

REDEEMABLE NONCONTROLLING INTERESTS**.**

The Company has noncontrolling interests with redemption features. These redemption features, such as put options, could require the Company to purchase the noncontrolling interests upon the occurrence of certain events. All noncontrolling interests with redemption features that are not solely within our control are recognized within the Condensed Consolidated Statements of Financial Position between liabilities and equity. Redeemable noncontrolling interests are initially recorded at the issuance date fair value. Those that are currently redeemable, or probable of becoming redeemable, are subsequently adjusted to the greater of current redemption value or initial carrying value.

Activity attributable to redeemable noncontrolling interests is presented below.


	For the six months ended June 30
	2026		2025
Balance at beginning of period	$	209	$	188
Net income attributable to redeemable noncontrolling interests	32		37

Distributions to redeemable noncontrolling interests and other	(12)		(5)
Balance at end of period	$	229	$	220

OTHER INCOME (EXPENSE) – NET.


	For the three months ended June 30				For the six months ended June 30
	2026		2025		2026		2025
Net financing income and investment income (loss)	$	7	$	6	$	6	$	5
Equity method income (loss)	—		1		(2)		4
Change in fair value of assumed obligations	(3)		(10)		(9)		(18)
Gain on remeasurement of NMP equity method investment(1)	—		—		—		97
Other items, net(2)	18		2		64		11
Total other income (expense) – net	$	22	$	(1)	$	58	$	98

(1) Refer to Note 7, “Acquisitions, Goodwill, and Other Intangible Assets” for additional information on the NMP acquisition.

(2) Other items, net primarily consists of a mix of licensing and royalty income, lease income, gains and losses related to derivatives, and change in tax indemnities. Additionally, for the six months ended June 30, 2026, it includes income from contract settlements, and for the six months ended June 30, 2025, it includes a realization of a gain contingency.

Table of Contents

Previous: Cover and table of contents · Next: Item 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS